RE:RE:RE:RE:First line maintenance therapy..You should probably keep your eye on this TH-1902 thing as it might yet turn the stock into something very special with more value creation than you can imagine at the moment. But things change fast when good results are achieved and we may be about 4 months away from just such good results. You should stop looking backward and assuming the failures of the past are going to repeat. There is likely a better than even chance of success in the restarted trial given the indication the drug was doing what is was supposed to in the earleier trials and the new approach with the reastarted trial which, as JFM pointed out (trusting your are well JFM) gives the drug many more opportunities to saturate the sortlin receptors on the cancer cells.
Trogarzon wrote: Any chance this company creates value or stop being witness to value destruction on a daily basis with their arms crossed.